Breaking News, Collaborations & Alliances

Kelun-Biotech Enters Collaboration & Exclusive License Agreement with MSD

Will develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.

Author Image

By: Charlie Sternberg

Associate Editor

Clinical-stage biotech company Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), has entered into a collaboration and exclusive license agreement with MSD (the tradename of Merck & Co., Inc Rahway NJ USA), to develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.   Under the terms of the agreement, Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC. Kelun-B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters